主页 > 医药生命 >
【medical-news】缬更昔洛韦：预防接受阿仑单抗治
Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells. Prophylaxis for herpes virus and pneumocystis carinii is standard with this agent. About 20-25% of patients will experience CMV reactivation.
We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily, or valganciclovir 450 mg orally twice daily. The study design planned to enroll 128 patients, but stopping rules for early termination were met. Forty patients were evaluable. Median age was 58 years (range 25-83); median number of prior therapies was 2 (0-10). Diagnoses included CLL (29), T-PLL (3), HCL (1), ATLL (1), marginal zone leukemia (1), LGL leukemia (2), ALL (1), T-cell lymphoma (2). Patients received varying alemtuzumab-containing regimens including single agent (5), or combined with: rituximab (2), pentostatin , fludarabine, cyclophosphamide, and rituximab (FCR) (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (Hyper CVAD)(4).
Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (p=0.004).
In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab.
http://www.docguide.com/news/content.nsf/PaperFrameSet?OpenForm&newsid=852571020057CCF6852573A2002D345A&topabstract=1&u=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18039954 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。
因个人有事，请求退出，表示抱歉！ 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy.
缬更昔洛韦：预防接受阿仑单抗治疗患者发生CMV激活
Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
阿仑单抗是一种针对T、B细胞的单克隆抗体。
Prophylaxis for herpes virus and pneumocystis carinii is standard with this agent. About 20-25% of patients will experience CMV reactivation.
预防疱疹病毒感染和卡氏肺囊虫感染已成为常规。大约有20-25%患者会发生CMV(巨细胞病毒)激活。
We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily, or valganciclovir 450 mg orally twice daily.
我们设计了一个随机试验：接受阿仑单抗治疗的病人被随机分为两组：分别预防性口服缬昔洛韦 500mg qd或者缬更昔洛韦450mg bid。
The study design planned to enroll 128 patients, but stopping rules for early termination were met.
试验计划入组128例患者，但是按一般性规则提前终止。
Forty patients were evaluable. Median age was 58 years (range 25-83); median number of prior therapies was 2 (0-10). Diagnoses included CLL (29), T-PLL (3), HCL (1), ATLL (1), marginal zone leukemia (1), LGL leukemia (2), ALL (1), T-cell lymphoma (2). Patients received varying alemtuzumab-containing regimens including single agent (5), or combined with:rituximab (2), pentostatin, fludarabine, cyclophosphamide, and rituximab (FCR) (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (Hyper CVAD)(4).
Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (p=0.004).
可评价病例40例，中位年龄58岁，预防治疗中位数2 (0-10)。病种包括CLL (29), T-PLL (3), HCL (1), ATLL (1),边缘区淋巴瘤(1)，大颗粒淋巴细胞白血病，ALL (1)，T细胞淋巴瘤(2)。病人接收了多种含有阿仑单抗治疗的方案，其中包括5例单用阿仑单抗治疗的，2例与利妥昔单抗合用，23例与FCR 方案组合，4例与Hyper CVAD方案组合的。7/20例接受缬昔洛韦预防CMV的治疗患者出现CMV的激活，0/20例接受缬更昔洛韦预防CMV的治疗患者出现CMV的激活。
In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab.
最后该实验强力推荐用缬更昔洛韦预防接受阿仑单抗治疗患者发生CMV激活。
翻译中这两个词很让我苦恼了一阵子：Valganciclovir缬更昔洛韦；valaciclovir缬昔洛韦。总以为是同一种药物。
抱着学习的目的第一次认领翻译，希望各位战友多赐教！ 缬更昔洛韦：预防接受阿仑单抗治疗患者发生CMV激活
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-25 17:19
医学,生命科学网